Equities

Fuji Pharma Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Fuji Pharma Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)2,395.00
  • Today's Change119.00 / 5.23%
  • Shares traded330.70k
  • 1 Year change+73.55%
  • Beta0.7778
Data delayed at least 15 minutes, as of Feb 18 2026 06:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Sep 30 2025202520242023
ASSETS
Cash And Short Term Investments7,2454,5852,324
Total Receivables, Net18,28318,87916,520
Total Inventory21,21518,00519,371
Prepaid expenses35109166
Other current assets, total1,135890733
Total current assets47,91342,46839,114
Property, plant & equipment, net20,91420,91120,547
Goodwill, net13,27911,7159,755
Intangibles, net662729738
Long term investments5,0947,09210,587
Note receivable - long term------
Other long term assets1,4221,7551,816
Total assets93,40590,00085,332
LIABILITIES
Accounts payable4,5704,1405,672
Accrued expenses1,105560883
Notes payable/short-term debt15,30015,30011,300
Current portion long-term debt/capital leases2,5637,6695,724
Other current liabilities, total7,4508,1286,192
Total current liabilities30,98835,79729,771
Total long term debt13,1516,37312,038
Total debt31,01429,34229,062
Deferred income tax------
Minority interest3.003.002.00
Other liabilities, total2,3582,2672,346
Total liabilities46,50044,44044,157
SHAREHOLDERS EQUITY
Common stock3,9043,7993,799
Additional paid-in capital4,5114,4064,409
Retained earnings (accumulated deficit)36,22234,26629,082
Treasury stock - common(498)(505)(567)
Unrealized gain (loss)(500)8852,414
Other equity, total3,2662,7092,038
Total equity46,90545,56041,175
Total liabilities & shareholders' equity93,40590,00085,332
Total common shares outstanding242424
Treasury shares - common primary issue0.440.440.45
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.